Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity

Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity

Thumbnail Image
Download
Name

s41467-017-02251-3.pdf

Size

4.46 MB

Format

Adobe PDF

Checksum (MD5)

c7b2335d87ee2b5bc17240134c5fabdc

Download all files submitted through automated deposit
sword-2018-04-27.original.zip (4.17 MB)
Author(s)
Zhang, Yuan
•
Li, Na
•
Suh, Heikyung
•
Irvine, Darrell J
Date Issued
January 2018
Journal
Nature Communications
Publisher
Nature Publishing Group
Citation
Zhang, Yuan et al. “Nanoparticle Anchoring Targets Immune Agonists to Tumors Enabling Anti-Cancer Immunity Without Systemic Toxicity.” Nature Communications 9, 1 (January 2018) © 2018 The Author(s)
Version
Final published version
Abstract
Immunostimulatory agents such as agonistic anti-CD137 and interleukin (IL)-2 generate effective anti-tumor immunity but also elicit serious toxicities, hampering their clinical application. Here we show that combination therapy with anti-CD137 and an IL-2-Fc fusion achieves significant initial anti-tumor activity, but also lethal immunotoxicity deriving from stimulation of circulating leukocytes. To overcome this toxicity, we demonstrate that anchoring IL-2 and anti-CD137 on the surface of liposomes allows these immune agonists to rapidly accumulate in tumors while lowering systemic exposure. In multiple tumor models, immunoliposome delivery achieves anti-tumor activity equivalent to free IL-2/anti-CD137 but with the complete absence of systemic toxicity. Immunoliposomes stimulated tumor infiltration by cytotoxic lymphocytes, cytokine production, and granzyme expression, demonstrating equivalent immunostimulatory effects to the free drugs in the local tumor microenvironment. Thus, surface-anchored particle delivery may provide a general approach to exploit the potent stimulatory activity of immune agonists without debilitating systemic toxicities.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Attribution 4.0 International (CC BY 4.0)
https://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/115183
DOI of Published Version
https://doi.org/10.1038/S41467-017-02251-3
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.